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Purpose: Late gastrointestinal (GI) toxicity after radiotherapy for prostate cancer may
have significant impact on the cancer survivor’s quality of life. To date, little is known
about local dose-effects after modern radiotherapy including hypofractionation. In the
current study we related the local spatial distribution of radiation dose in the rectum to
late patient-reported gastrointestinal (GI) toxicities for conventionally fractionated (CF) and
hypofractionated (HF) modern radiotherapy in the randomized HYPRO trial.
Material and Methods: Patients treated to 78Gy in 2Gy fractions (n= 298) or 64.6Gy
in 3.4Gy fractions (n = 295) with available late toxicity questionnaires (n ≥ 2 within 1–5
years post-treatment) and available 3D planning data were eligible for this study. The
majority received intensity modulated radiotherapy (IMRT). We calculated two types of
dose surface maps: (1) the total delineated rectum with its central axis scaled to unity,
and (2) the delineated rectum with a length of 7 cm along its central axis aligned on
the prostate’s half-height point (prostate-half). For each patient-reported GI symptom,
dose difference maps were constructed by subtracting average co-registered EQD2
(equivalent dose in 2Gy) dose maps of patients with and without the symptom of interest,
separately for HF and CF. P-values were derived from permutation tests. We evaluated
patient-reported moderate to severe GI symptoms.
Results: Observed incidences of rectal bleeding and increased stool frequency were
significantly higher in the HF group. For rectal bleeding (p = 0.016), mucus discharge
(p = 0.015), and fecal incontinence (p = 0.001), significant local dose-effects were
observed in HF patients but not in CF patients. For rectal pain, similar local dose-effects
(p< 0.05) were observed in both groups. No significant local dose-effects were observed
for increased stool frequency. Total rectum mapping vs. prostate-half mapping showed
similar results.
Conclusion: We demonstrated significant local dose-effect relationships for
patient-reported late GI toxicity in patients treated with modern RT. HF patients were
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at higher risk for increased stool frequency and rectal bleeding, and showed the most
pronounced local dose-effects in intermediate-high dose regions. These findings suggest
that improvement of current treatment optimization protocols could lead to clinical
benefit, in particular for HF treatment.
Keywords: prostate cancer, hypofractionation, gastrointestinal toxicity, dose-surface maps, radiotherapy, NTCP
INTRODUCTION
Irradiation of tumors in the pelvic area through external beam
radiotherapy comes inevitably with dose delivery to nearby
organs at risk, such as the rectum. The potential permanent
impact of late gastrointestinal (GI) toxicity after radiotherapy
may have significant impact on the cancer survivor’s quality of life
(1). Preventing chronic late GI toxicity is therefore critical. For
this purpose understanding how we should distribute radiation
dose to surrounding normal tissues while keeping toxicity risks
as low as possible is critical.
The QUANTEC project (quantitative analysis of normal tissue
effects in the clinic) previously summarized the available clinical
data and models on acute and late radiation-induced toxicities
with the goal to improve patient care by providing useful
tools (2). These models were mainly derived from traditionally
fractionated 3D conformal radiotherapy (3DCRT). Shortcomings
and open issues of the available models have broadly been
recognized, including the uncertainty of fractionation effects,
a lack of reliable models for modern radiotherapy with
IMRT dose distributions and image-guidance, and a lack
of knowledge concerning spatial effects (3). This causes a
number of deficits in current strategies of treatment planning
optimization in the current era of IMRT, image-guidance, and
hypofractionated treatment.
With respect to the inhomogeneous dose distributions
in the rectum, achieved with either radiation technique or
fractionation schedule, we can theoretically translate physical
dose distributions into (radio)biological dose parameters using
mathematical models derived from radiobiology (4, 5). Altered
fractionation schedules in recent hypofractionation trials in
prostate cancer are based on such models (6–9). However, to
achieve reliable biological NTCP models for late GI toxicity after
modern RT, we first have to gain insight into local dose-effects
and (hypo)fractionation effects in real patient populations rather
than depending solely on theoretical models.
Historically, dose-response for normal tissues were evaluated
taking dose-volume distributions to a whole single organ into
consideration. It is nowadays recognized that function and
radiosensitivity may vary within an organ, and that dose-shapes
might be relevant. Therefore, local spatial dose evaluations
beyond the boundaries of delineations and dose-volume may
enhance our understanding of mechanisms causing radiation-
induced damage (10). In particular voxel-based dose mapping
procedures have been introduced to take into account the
spatial dose distribution by co-registering dose distributions to
a region of interest, often using a template patient. For hollow
organs such as the rectum, a spatial 2D dose distribution of
the rectal wall (i.e., virtual unfolding of the rectum to a 2D
structure) is considered reasonably sufficient for this purpose
(11–18). Evaluation of local rectal and anal dose distributions
in relation to acute and late gastrointestinal toxicity endpoints
by means of dose mapping have been previously performed by
several research groups. This concerned mainly patients treated
with conventional fractionation schedules, identifying local dose
effects for various endpoints including rectal bleeding, fecal
leakage, and increased stool frequency (11–18).
In the current study we explored local rectal dose
distributions and their relation to GI toxicity endpoints,
for both hypofractionated (HF) and conventionally fractionated
(CF) treatment, using toxicity data and planning data from
the HYPRO trial. In this trial patients were randomized
between conventional and hypofractionated treatment,
delivered with modern radiotherapy techniques including
IMRT, image-guidance, and online prostate position verification.
MATERIALS AND METHODS
Patient Selection
The dataset of a recent Dutch randomized clinical trial (HYPRO)
was analyzed in which patients were randomized to 78Gy in
conventional 2Gy fractions (CF) or 64.4Gy in hypofractionated
3.4Gy fractions (HF) (19). Selected patients were eligible for the
current study in case both late toxicity data (n≥ 2 questionnaires
within the period 1–5 year post-treatment (N = 633,Table 2) and
3D planning data were available (which were not available for
40 patients), leaving 593 patients for the current study. Because
planning of patient visits may vary from the study schedule, we
accepted questionnaires up to 5.5 year post-treatment.
Treatment
Based on an estimated α/β for prostate cancer of 1.5Gy, the
EQD2 was 90.4Gy for HF vs. 78.0Gy for CF. For normal rectal
tissue with an estimated α/β of 3Gy, the EQD2 was 82.7Gy
for HF vs. 78.0 for CF. The clinical target volume was the
prostate with or without the seminal vesicles (SV): based on the
estimated risk of SV involvement according Partin tables (20),
a SV dose of 0Gy, 72.2Gy, or 78Gy was planned (19). The
outer contours of the rectum were delineated on the planning CT
scan from the anal verge to the bottom of the sacro-iliac joints.
The HYPRO protocol prescribed that the rectal volume receiving
83% of the prescribed dose should be below 50% for the total
rectal volume or below 60% for the rectal wall. Further treatment
optimization was performed in accordance with local protocols
at each participating center. The applied treatment technique for
99% of the patients was image-guided IMRT with daily online
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positioning of the prostate. For this purpose, cone beam CT was
used in 23% and portal imaging devices was used in 77% of the
cases. A small proportion was treated with 3DCRT (1%). One
center applied a rectal balloon, which pushes the posterior rectal
wall out of the intermediate dose region (21). Further details of
treatment planning have been previously reported (6, 19). CF
patients received 5 fractions per week, andHF patients 3 fractions
per week with 1 day intervals (Monday, Wednesday, Friday).
Toxicity Endpoints
The patient-reported GI symptoms were extracted from a
patient-reported symptom list (questionnaire) distributed in the
HYPRO trial at the late time points of 6 months, and yearly
between 1 and 5 year (22). Evaluated GI symptoms were: rectal
bleeding, fecal incontinence, pain/cramps with stools, mucus
discharge (all had to be reported as moderate or severe to be
scored), and increased stool frequency≥ 4 per day. We identified
from all available questionnaires the maximum score for each
toxicity endpoint of interest.
Dose-Surface Maps
For the rectal wall the dose surface mapping was based on
a central axis which was first computed as the maximum of
a Euclidean distance transform. The average length of the
delineated rectum along the central axis was 14.9 cm for both
HF and CF. The intersections of equidistant slices perpendicular
to this axis with the delineated rectum surfaces provided the
corresponding locations between patients. We calculated two
types of dose surface maps: (1) “total rectum mapping”: the
delineated rectum with its central axis scaled to unity, and
(2) “prostate half mapping”: the delineated rectum next to the
prostate with a length of 7 cm along the central axis (plus 4 cm in
cranial direction and minus 3 cm in caudal direction, measured
from the half-height position of the prostate). These cutoffs were
chosen to cover the dose range in the rectum of about 50–100%
of the prescribed dose.
To correct a patient averaged dose-surface map for
fractionation effects using the linear-quadratic model (i.e.,
equivalent dose in 2 Gy: EQD2), we applied a chosen α/β ratio
of 3Gy to the dose distribution of each patient. The resolution
of the dose maps was chosen to effectively slightly exceed a
2mm dose grid resolution. In the circumferential direction 90
pixels were taken, i.e., every 4 degrees. In the axis direction of
rectum maps 100 pixels were taken, which would effectively
cover a 15 cm long rectum at 1.5mm resolution. As a final step,
resulting dose-surface maps of individual patients (physical
and biological) could be averaged and subtracted for each
identified toxicity endpoint (yes vs. no). Further details have
been previously reported (14).
Statistical Analysis
Distributions of baseline characteristics within the HF and CF
group were calculated and tested for differences applying a
Chisquare test for the ordinal and binary variables, and a T-
test for age. Associations between clinical covariates and toxicity
endpoints were tested univariate using binary logistic regression.
For each evaluated GI symptom, dose difference maps were
constructed by subtracting average EQD2 dose maps of patients
with and without the toxicity of interest, separately for HF and
CF. For the calculation of a p-value for each dose difference
map, we used a permutation approach, randomly re-shuffling
the patients among the subgroups (23). For the determination
of significant differences within a dose-difference map, we
calculated and evaluated the false discovery rates “q” as a realistic
estimate of the local p-values, which is a practical and powerful
approach to tackle the multiple testing issue (24, 25).
RESULTS
Baseline Characteristics
The baseline characteristics of the selected study patients are
summarized in Table 1 which shows that distribution of the
characteristics are similar for HF and CF except for a history
of TURp which was more common in the CF group (11
vs. 7%, p= 0.07, Table 1). A history of TURp was however
not associated with any of the evaluated moderate to severe
GI symptoms.
Reported GI Toxicities
In Table 2, the observed incidences of the late GI toxicities
of interest are summarized per treatment group, both for all
patients in the HYPRO trial who filled out≥2 late questionnaires
(N = 633) and for the selected group with available CT scans
and dose distributions (N = 593). These are the result of
accumulation over all available questionnaires between Year 1
and Year 5, taking maximum scores. The table shows that the
selected population with available dose information, was a non-
biased and representative selection of the patient group that filled
out late questionnaires.
TABLE 1 | Patient and treatment characteristics (N = 593).
Variable CF (n = 298) HF (n = 295) p-value#
Age (mean, sd) in years 70.1 (6.0) 69.5 (6.6) 0.2
TURp 11% 7% 0.07
Abdominal surgery 26% 25% 0.7
Diabetes mellitus 13% 14% 0.5
Adjuvant hormonal therapy 65% 63% 0.6
Fiducial markers 95% 95% 0.9
IMRT 98% 99% 0.3
T category
T1-2 46% 48% 0.7
T3-4 54% 52%
PTV margins prostate
5-7mm 89% 89% 0.9
8-10mm 11% 11%
Dose seminal vesicles
0Gy 23% 20% 0.4
72-78Gy 77% 80%
#p-values calculated with Chisquare test, except for age (t-test).
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About 35% of CF and HF patients experienced one or more
moderate to severe late symptoms after modern RT, accumulated
over the evaluated late period (Table 2). Compared to CF,
significantly higher incidences after HF treatment were observed
for the late endpoints of rectal bleeding and increased stool
frequency. More HF patients experienced multiple moderate to
severe GI symptoms.
Among the late GI endpoints of study, all endpoints showed
significant correlations with the other ones (i.e., if a patient
reported 1 symptom it was likely that he also reports one or more
of the other symptoms). Highest correlations were observed
between fecal incontinence-increased stool frequency, and rectal
bleeding-mucus discharge (p< 0.001).
Associations Between Clinical Covariates
and Toxicity Endpoints
The results of assessing the associations between baseline
covariates and the toxicity endpoints of interest are summarized
in Table 3. Rectal incontinence was significantly associated with
diabetes and age. Rectal bleeding and mucus discharge were
significantly associated with T stage.
Dose-Surface Maps
Figure 1 shows the average EQD2 dose-surface maps and local
standard deviations for both types of mapping and for both
groups (CF and HF). Comparing the EQD2 dose distributions of
CF and HF, we observed that the high-dose area is darker red for
HF which can be explained by the somewhat higher prescription
dose in EQD2 for HF (82.7Gy vs. 78Gy). Furthermore, the rectal
surface receiving dose levels in the range of ≥ 1–≥ 65Gy EQD2
look very similar for HF and CF, whereas the rectal surface
receiving dose levels in the range of > 65–≥ 80Gy EQD2 were
on average different with larger surfaces for HF. From previous
calculations of “traditional” whole organ dose-surface histograms
(DSH), it is known that indeed the average DSH of HF vs. CF
only show a slightly unfavorable dose level in the range of > 65–
≥ 80Gy EQD2 (supporting DSH figure in Supplementary File).
Furthermore, local standard deviations were larger for HF. The
rectum adjacent to the prostate, as shown on the prostate-half
maps, received dose levels in the range of 20–80Gy, with the
largest standard deviations (i.e., variation between patients) at
the cranial and caudal side. The total rectum maps show dose
levels in the range of 0–80Gy, with 0–10Gy in the most caudal
15% (the anal canal region) and the most cranial part close to the
rectosigmoid region.
Dose-Difference Maps
For each toxicity endpoint, four dose difference maps were
constructed: total rectum mapping and prostate-half mapping,
and for each type of mapping the HF and CF version
(Figures 2, 3). In general, one or more significant dose difference
maps were obtained for all GI endpoints except for increased
stool frequency (lowest observed p = 0.086). All dose-difference
maps were also generated with physical dose instead of EQD2
dose, to check whether this might change results. Since they were
very similar to the EQD2 versions, we report here only results
based on EQD2 dose maps.
For rectal bleeding, large local dose differences (p = 0.016)
up to ≥10Gy were observed between patients with and
without this complaint (Figures 2, 3), but only for HF patients.
Remarkably, the prostate-half mapping (Figure 3) indicates
significant differences in the region next to the prostate, whereas
the total rectum mapping (Figure 3) indicates local dose-effects
at a more cranial part of the rectum. Both locations are regions
were on average ≈60Gy (EQD2) is received by the rectal tissue
(Figure 1).
For the late endpoint fecal incontinence, highly significant
local dose-effects were found for the region receiving
intermediate to high dose, i.e., in the neighborhood of the
prostate (Figures 2, 3), but again only for HF patients. For
mucus discharge, we also observed local dose-effects for HF
patients only, which were identified by the total rectum mapping
(Figure 2). Pain/cramps with stools was associated with local
TABLE 2 | Incidence of late gastrointestinal toxicity endpoint (evaluated by the patient as “moderate—severe”) on questionnaires in the period 1–5 year post-treatment.
≥2 questionnaires (N = 633) With available dose maps (N = 593)
CF HF p CF HF p
n = 310 n = 323 n = 298 n = 295
Late GI endpoint
Stool frequency ≥4/day 12.3% 19.5% 0.013 12.1% 19.7% 0.011
Rectal bleeding 11.0% 16.7% 0.037 10.7% 17.6% 0.016
Mucus discharge 5.2% 6.2% 0.6 5.0% 6.4% 0.5
Pain/cramps with stools 7.4% 9.9% 0.3 7.7% 10.2% 0.3
Fecal incontinence 10.6% 11.1% 0.8 10.7% 11.5% 0.8
≥1 symptom 30.3% 35.6% 0.16 30.2% 36.3% 0.12
≥2 symptoms 12.6% 18.0% 0.061 12.4% 19.3% 0.020
≥3 symptoms 3.2% 6.8% 0.040 3.4% 7.1% 0.040
P <0.05 are indicated in bold. GI, gastrointestinal; HF, hypofractionation; CF, conventional fractionation.
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TABLE 3 | Association between clinical baseline covariates and toxicity endpoints.
Stools ≥ 4/day Rectal bleeding Mucus discharge Pain/cramps Fecal incontinence
HR p HR p HR p HR p HR p
Age > 70 vs. ≤ 70 0.87 0.5 0.89 0.6 0.61 0.2 0.63 0.1 2.67 <0.01
TURp yes vs. no 1.19 0.6 0.90 0.8 1.34 0.6 0.37 0.2 1.96 0.07
Previous abdominal surgery yes vs. no 0.76 0.3 1.23 0.4 0.47 0.1 1.14 0.7 1.26 0.4
Diabetes yes vs. no 1.21 0.05 0.84 0.6 no result 0.97 0.9 2.05 0.024
AHT yes vs. no 1.02 0.9 1.11 0.7 1.98 0.09 0.63 0.1 1.16 0.6
T3-4 vs. T1-2 1.00 1.0 1.60 0.046 2.13 0.04 1.00 1.0 0.87 0.6
P <0.05 are indicated in bold. Results from univariate logistic regression (N = 633). OR, Odds ratio; TURp, transurectal resection of prostate; AHT, adjuvant hormonal therapy; SV,
seminal vesicles.
FIGURE 1 | Total rectum (upper panes) and prostate-half (lower panes) mean dose-surface maps with distance along central axis (vertical) against location along
circumference axis (horizontal). Left panes represent mean dose-surface maps of conventionally fractionated patients, right panes for hypofractionated patients. EQD2
= equivalent dose for 2Gy fractions with α/β =3Gy. Abbreviations: P, posterior; R, right; L, left; A, anterior; SD, standard deviation.
dose distributions in CF patients; for HF patients no such effect
was observed (Figure 2).
DISCUSSION
We explored local dose-effect relationships for GI toxicity in a
study population treated with both conventionally fractionated
and hypofractionated modern radiotherapy. Since both patient
groups were treated within the same randomized trial, this is
a unique dataset to study hypofractionation effects on rectal
toxicity with a perfect internal reference group of CF patients.
We observed significant local dose-effect relations for all studied
GI endpoints, except for increased stool frequency. For the
endpoints rectal bleeding, pain/cramps, and mucus discharge, we
observed differences between HF and CF in the patterns and
level of significance of local dose-effects, whereas for pain or
cramps with stools, observed patterns and levels of significance
were similar.
We evaluated two types of dose mapping. The “total rectum”
mapping is more accurate in matching specific anatomical sub-
locations within the rectum between different patients an also
covers the most cranial and caudal part of the rectum, whereas
the “prostate-half ” mapping is more accurate in matching the
intermediate-high dose areas behind the prostate from one
patient to another. The identified local dose-effects for both types
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FIGURE 2 | Dose difference maps (1EQD2) based on total rectum dose mapping, for the toxicity endpoints (moderate to severe), for the hypofractionated and
conventional group separately. EQD2 = equivalent dose for 2Gy fractions with α/β = 3Gy, q = false discovery rate. Abbreviations: P, posterior; R, right; L, left; A,
anterior.
ofmapping were similar with comparable p-values. Theoretically,
we expected that the prostate-half mapping would be more
accurate in identifying risks associated with high-dose regions
close to the prostate and is therefore of added value to the total
rectum mapping which covers the whole anorectal tract, which
was demonstrated in a previous study (14). However, we could
not confirm this in the current study.
In the current study we used patient-reported toxicity
from a prospective setting, accumulating the incidence over
available questionnaires between year 1 and 5. As a result,
30% (CF) and 36% (HF) reported ≥1 moderate to severe
complaint within this period. Previously, we reported that at
36 months of follow-up, 36% (CF), and 38% (HF) had a
clinically relevant deterioration on the gastrointestinal subscale
of the Prostate Cancer 25 Quality of Life module (26), which
is in fair agreement with the current findings based on the
symptom questionnaire. As discussed in this previous paper
(26), reported toxicity incidences and differences between CF
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FIGURE 3 | Dose difference maps (1EQD2) based on prostate-half height dose mapping, for the toxicity endpoints (moderate to severe), for the hypofractionated and
conventional group separately. EQD2 = equivalent dose for 2Gy fractions with α/β = 3Gy, q = false discovery rate. Abbreviations: P, posterior; R, right; L, left; A,
anterior.
and HF in the HYPRO trial are unfavorable compared to the
CHHIP trial (7), which may have been caused by differences
in target definition (for most HYPRO patients inclusion of
the seminal vesicles), different patient population (HYPRO
patients were mainly high-risk patients), and especially by a
greater difference in EQD2 dose levels (with an α/β of 3 for
normal tissue): 78Gy (CF) vs. 82.7Gy (HF) for the HYPRO
trial, and 74Gy (CF) vs. 72Gy (HF – 20 × 3) for the
CHHIP trial.
As reported by several previous studies, prospective
registration translates in general into relatively high incidences
of toxicity when compared to studies where only physician-
reported toxicities are used, as we also previously demonstrated
for the HYPRO trial (19). When we compare our patient-
reported rates of rectal bleeding and fecal incontinence with the
recent study of Onjukka et al. who also used patient-reported
late toxicity in a modern IMRT setting with mainly conventional
fractionation and partly mild hypofractionation, the reported
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rates are very similar for both endpoints: about 10% in both
studies (18).
We found that patient-reported GI toxicity incidences were
higher for HF compared to CF with respect to the endpoints
≥3 symptoms, stool frequency, and rectal bleeding. Furthermore,
we demonstrated that after converting both the HF and CF
dose maps with the linear-quadratic model (with α/β of 3Gy)
to EQD2, we obtained very different dose-difference maps
(Figures 2, 3) where we would expect similar local dose-effects.
This suggests that just by calculating EQD2 for a HF schedule,
this might not completely capture the biological effect of a HF
treatment. There are several differences between the HF and CF
group which might have contributed to the observations of both
higher incidences and different dose-difference maps: (a) applied
dose constraints were based on earlier studies with CF; (b) the
rectum dose for HF was on average somewhat higher because of
the higher EQD2 prescription dose of 82.7Gy with α/β = 3; (c)
local dose variations (standard deviations) were larger for the HF
group; and (d) HF was delivered three times a week with 3.4Gy
fractions instead of 5 times a week 2 Gy fractions.
The symptom rectal bleeding was highly correlated with
mucus discharge, which can be expected since both symptoms are
the result of a radiation proctitis. In the literature, the endpoint
of rectal bleeding has been extensively studied and modeled since
it is regarded as a dose-limiting late toxicity (3). We observed
a significantly higher incidence of patient-reported moderate to
severe late rectal bleeding for HF compared to CF (17.6% vs.
10.7%). We previously reported the EORTC/RTOG grade ≥2
incidence of rectal bleeding (requiring clotting time), which was
also higher for HF patients (5 vs. 2%, p = 0.11). (22). For rectal
bleeding pronounced local dose-effects were observed in the
dose-difference maps in the moderate to high-dose rectal regions
close to the prostate, but only for HF patients. The location is in
general in concordance with the literature based on conventional
treatment, were high-dose regions above ≈60–70Gy are found
to be relevant for rectal bleeding. Applied dose constraints in the
clinic are based on these published models (3). In the HYPRO
trial, rectal volumes receiving ≥83% of the prescribed dose (i.e.,
≥65Gy for CF and≥54Gy for HF) had to be limited at treatment
optimization to ≤50%. Our results suggest that for HF this
planning criterion was suboptimal, resulting in increased risks of
rectal bleeding. However, this observation might also be in part
related to the higher EQD2 prescription dose of 82.7 Gy.
We observed similar fecal incontinence rates between CF and
HF, but higher rates of increased stool frequency forHF (Table 2).
At the same time, these complaints were highly correlated. In a
recent study of Cicchetti et al. (27), comparing CF with mild HF
(2.25–2.75Gy per fraction), higher levels of fecal incontinence
were observed for mild HF compared to CF. For the endpoints
increased stool frequency and fecal incontinence, dose to other
neighboring structures, such as pelvic floor muscles and nerves,
might be relevant as well, as reported in several studies (28, 29).
However, in other studies, similar rates of fecal incontinence
were observed between 3DCRT and IMRT groups whereas the
latter was associated with largely reduced dose levels to the anal
canal region (27, 30) which is in the same region as the pelvic
floor muscles.
As previously published, the results of the HYPRO trial were
negative with respect to its hypothesis, i.e., non-inferiority with
respect to Grade ≥2 toxicity and superiority with respect to
freedom from failure could both not be demonstrated for the
HF arm (6). Therefore, is this hypofractionation schedule of
19 times 3.4Gy not recommendable or acceptable for clinical
practice. However, for studying hypofractionation effects and
dose-effect relationships these data are very useful. In current
clinical practice, the hypofractionation schedule of the CCHIP
trial (7) and the Widmark trial (9) have been adopted by centers
worldwide, in which hypofractionated treatment is distributed
over several weeks of treatment with intervals >24 h between
fractions, similar to the HYPRO trial. To understand more about
fractionation effects and effects of intervals between fractions on
late (permanent) damage to normal tissues, additional modeling
of the dose and outcome data from hypofractionation trials is
essential. Recently, Wilkins et al. reported on dose-effect analyses
from the CCHIP trial, derived from both conventional whole
organ evaluation and from spatial dose mapping, aiming at
formulating novel dose constraints for mild hypofractionation
regimens in 3Gy fractions (31). They report that different rectal
dose constraints were obtained for different GI symptoms. In
their study, spatial dose metrics did not improve prediction
compared to dose-volume information.
Data from the hypofractionated trial arm of the HYPRO trial
have been used for toxicity modeling using dose-volume data
and additional features derived from texture analysis (32). They
reported models for the GI symptoms of fecal incontinence and
rectal modeling including clinical factors, dose-volume factors,
and derived texture features. From other phase III randomized
hypofractionation trials (6–9, 33), there are to our knowledge no
publications yet on additional dose-effect modeling.
It is nowadays broadly recognized that incorporating
spatial local dose information from voxel-based organ-at-risk
calculations, in contrast to whole organ evaluations, has the
potential to improve NTCP models and therefore improve the
quality of derived planning constraints (10). Several studies
have demonstrated that spatial local dose metrics are suitable
for NTCP modeling of rectal toxicity compared to traditional
dose-surface (DSH) and dose-volume histograms (DVH) (12–
18). Recently, Casares et al. (34) reported on the superiority
of spatial metric by comparing NTCP models; they concluded
that predictability of patient-reported GI toxicity increased using
spatial metrics compared to DSH/DVH metrics. The HYPRO
data set is a very suitable dataset for bioeffect modeling of
toxicity with the goal to obtain meaningful NTCP models and
related dose constraints for optimized treatment planning with
modern techniques including hypofractionation. An essential
question to answer prior to the modeling is: how to summarize
the inhomogeneous dose distributions into meaningful dose
parameters for subsequent modeling. The dose maps resulting
from this study clearly show that especially intermediate-
high dose areas in the rectum are associated with a number
of GI symptoms, especially for HF treatment. As previously
described by Bentzen et al. (4), true equieffective dose levels
(with the same bioeffect) result in identical toxicity risks.
Further modeling of the HYPRO data, by constructing NTCP
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models based on calculated EQD2 dose for each group, may
demonstrate whether the calculated EQD2 levels are equieffective
or whether other biological factors have to be taken into
account to calculate the true biological equieffective dose.
Furthermore, relevant clinical covariates have to be incorporated
into such models as well to improve the predictive power
of such models. As shown in Table 3, for the endpoint
fecal leakage (age and diabetes) and for the endpoints rectal
bleeding and mucus (T stage) predictive clinical covariates
were identified. Our ultimate goal is to use the current
findings to develop a biological NTCP model that correctly
incorporates fractionation effects, modeling the GI toxicity as
a function of biological dose. This could then theoretically be
applied to all types of dose distributions including different
fractionation schedules.
In conclusion, we demonstrated significant local dose-effect
relationships for patient-reported late GI toxicity in patients
treated with modern RT. HF patients were at higher risk for
increased stool frequency and rectal bleeding, and showed the
most pronounced local dose-effects in intermediate-high dose
regions. These findings suggest that improvement of current
treatment optimization protocols could lead to clinical benefit,
in particular for HF treatment.
DATA AVAILABILITY STATEMENT
The datasets used in this study are available on request. The
corresponding author can be contacted for this purpose.
ETHICS STATEMENT
This trial was approved by the Medical Ethics Committee of the
ErasmusMedical Center in Rotterdam, theNetherlands (06-045).
The patients/participants provided their written informed
consent to participate in this study.
AUTHOR CONTRIBUTIONS
MW and WH contributed to the study design (patient selection,
endpoint definitions, dose mapping procedures, statistical
analyses) and writing of the drafts of the manuscript. LI and
FP contributed to patient inclusion and follow-up. MW and BH
contributed to data collection of dosimetric data. All authors
contributed to critical reading, revision of the manuscript, and
approval of the submitted version.
FUNDING
The HYPRO trial was financially supported by the Dutch
Cancer Society (Grant No. CKTO 2006-08) which is a non-
profit organization.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fonc.
2020.00469/full#supplementary-material
REFERENCES
1. Donovan JL, Hamdy FC, Lane JA,MasonM,Metcalfe C,Walsh E, et al. Patient
reported outcomes after monitoring, surgery, or radiotherapy for prostate
cancer. N Engl J Med. (2016) 375:1425–37. doi: 10.1056/NEJMoa1606221
2. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch
A, et al. Use of normal tissue complication probability models in
the clinic. Int J Radiat Oncol Biol Phys. (2010) 76(Suppl. 3):S10–
9. doi: 10.1016/j.ijrobp.2009.07.1754
3. Landoni V, Fiorino C, Cozzarini C, Sanguinet G, Valdagni R, Rancati T.
Predicting toxicity in radiotherapy for prostate cancer. Phys Med. (2016)
32:521–32. doi: 10.1016/j.ejmp.2016.03.003
4. Bentzen SM, Dörr W, Gahbauer R, Howell RW, Joiner MC, Jones B,
et al. Bioeffect modeling and equieffective dose concepts in radiation
oncology—terminology, quantities and units. Radiother Oncol. (2012)
105:266–8. doi: 10.1016/j.radonc.2012.10.006
5. Fowler JF. The radiobiology of prostate cancer including
new aspects of fractionated radiotherapy. Acta Oncol. (2005)
44:265–76. doi: 10.1080/02841860410002824
6. Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S,
et al. Hypofractionated versus conventionally fractionated radiotherapy for
patients with localised prostate cancer (HYPRO): final efficacy results from
a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. (2016)
17:1061–69. doi: 10.1016/S1470-2045(16)30070-5
7. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield, D,
et al. Conventional versus hypofractionated high-dose intensity-modulated
radiotherapy for prostate cancer: 5-year outcomes of the randomised,
non-inferiority, phase 3 CHHiP trial. Lancet Oncol. (2016) 17:1047–
60. doi: 10.1016/S1470-2045(16)30102-4
8. Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, et al.
Randomized phase III noninferiority study comparing two radiotherapy
fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol.
(2016) 34:2325–32. doi: 10.1200/JCO.2016.67.0448
9. Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, HoyerM,
LagerlundM, et al. Ultra-hypofractionated versus conventionally fractionated
radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-
PC randomised, non-inferiority, phase 3 trial. Lancet. (2019) 394:385–
95. doi: 10.1016/S0140-6736(19)31131-6
10. Palma G, Monti S, Cella L. Voxel-based analysis in radiation
oncology: a methodological cookbook. Phys Med. (2020) 69:192–
204. doi: 10.1016/j.ejmp.2019.12.013
11. Heemsbergen WD, Hoogeman MS, Hart GA, Lebesque JV, Koper PC.
Gastrointestinal toxicity and its relation to dose distributions in the anorectal
region of prostate cancer patients treated with radiotherapy. Int J Radiat Oncol
Biol Phys. (2005) 61:1011–8. doi: 10.1016/j.ijrobp.2004.07.724
12. Buettner F, Gulliford SL, Webb S, Sydes MR, Dearnaley DP, Partridge M.
Assessing correlations between the spatial distribution of the dose to the
rectal wall and late rectal toxicity after prostate radiotherapy: an analysis of
data from the MRC RT01 trial (ISRCTN 47772397). Phys Med Biol. (2009)
54:6535–48. doi: 10.1088/0031-9155/54/21/006
13. Buettner F, Gulliford SL, Webb S, Sydes MR, Dearnaley DP, Partridge
M. The dose-response of the anal sphincter region–an analysis of
data from the MRC RT01 trial. Radiother Oncol. (2012) 103:347–
52. doi: 10.1016/j.radonc.2012.03.002
14. Wortel RC, Witte MG, van der Heide UA, Pos FJ, Lebesque JV, van
Herk M, et al. Dose-surface maps identifying local dose-effects for acute
gastrointestinal toxicity after radiotherapy for prostate cancer. Radiother
Oncol. (2015) 117:515–20. doi: 10.1016/j.radonc.2015.10.020
15. Acosta O, Drean G, Ospina JD, Simon A, Haigron P, Lafond C, de Crevoisier
R. Voxel-based population analysis for correlating local dose and rectal
toxicity in prostate cancer radiotherapy. Phys Med Biol. (2013) 58:2581–
95. doi: 10.1088/0031-9155/58/8/2581
Frontiers in Oncology | www.frontiersin.org 9 April 2020 | Volume 10 | Article 469
Heemsbergen et al. Dose-Surface Maps Gastrointestinal Toxicity
16. Munbodh R, Jackson A, Bauer J, Schmidtlein CR, Zelefsky MJ. Dosimetric
and anatomic indicators of late rectal toxicity after high-dose intensity
modulated radiation therapy for prostate cancer. Med Phys. (2008) 35:2137–
50. doi: 10.1118/1.2907707
17. Moulton CR, House MJ, Lye V, Tang CI, Krawiec M, Joseph DJ, et al. Spatial
features of dose-surface maps from deformably-registered plans correlate
with late gastrointestinal complications. Phys Med Biol. (2017) 62:4118–
39. doi: 10.1088/1361-6560/aa663d
18. Onjukka E, Fiorino C, Cicchetti A, Palorini F, Improta I, Gagliardi G, et al.
Patterns in ano-rectal dose maps and the risk of late toxicity after prostate
IMRT. Acta Oncol. (2019) 58:1757–64. doi: 10.1080/0284186X.2019.1635267
19. Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP,
et al. Hypofractionated versus conventionally fractionated radiotherapy
for patients with prostate cancer (HYPRO): acute toxicity results from
a randomised non-inferiority phase 3 trial. Lancet Oncol. (2015) 16:274–
83. doi: 10.1016/S1470-2045(14)70482-6
20. Partin W, Mangold LA, Lamm DM, Walsh PC, Epstein JI,
Pearson JD. Contemporary update of prostate cancer staging
nomograms (partin tables) for the new millennium. Urology. (2001)
58:843–8. doi: 10.1016/s0090-4295(01)01441-8
21. Wortel RC, Heemsbergen WD, Smeenk RJ, Witte MG, Krol SDG, Pos FJ,
et al. Local protocol variations for image guided radiation therapy in the
multicenter dutch hypofractionation (HYPRO) trial: impact of rectal balloon
and mri delineation on anorectal dose and gastrointestinal toxicity levels. Int
J Radiat Oncol Biol Phys. (2017) 99:1243–52. doi: 10.1016/j.ijrobp.2017.07.044
22. Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager
H, et al. Hypofractionated versus conventionally fractionated radiotherapy
for patients with prostate cancer (HYPRO): late toxicity results from a
randomised, non-inferiority, phase 3 trial. Lancet Oncol. (2016) 17:464–
74. doi: 10.1016/S1470-2045(15)00567-7
23. Chen, C, Witte, M, Heemsbergen, W, van Herk, M, Multiple comparisons
permutation test for image based data mining in radiotherapy. Radiat Oncol.
(2013) 8:293. doi: 10.1186/1748-717X-8-293
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J R Statist Soc B. (1995) 57:289–300.
25. Dréan G, Acosta O, Ospina JD, Fargeas A, Lafond C, Corrégé G,
et al. Identification of a rectal subregion highly predictive of rectal
bleeding in prostate cancer IMRT. Radiother Oncol. (2016) 119:388–
97. doi: 10.1016/j.radonc.2016.04.023
26. Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, Incrocci
L. Moderate hypofractionation in intermediate- and high-risk, localized
prostate cancer: health-related quality of life from the randomized,
phase 3 hypro trial. Int J Radiat Oncol Biol Phys. (2019) 103:823–
33. doi: 10.1016/j.ijrobp.2018.11.020
27. Cicchetti A, Avuzzi B, Palorini F, Ballarini F, Stucchi C, Fellin G, et al.
Predicting late fecal incontinence risk after radiation therapy for prostate
cancer: new insights from external independent validation. Int J Radiat Oncol
Biol Phys. (2018) 102:127–36. doi: 10.1016/j.ijrobp.2018.05.013
28. Schaake W, van der Schaaf A, van Dijk LV, Bongaerts AH, van den
Bergh AC, Langendijk JA. Normal tissue complication probability (NTCP)
models for late rectal bleeding, stool frequency and fecal incontinence after
radiotherapy in prostate cancer patients. Radiother Oncol. (2016) 119:381–7.
doi: 10.1016/j.radonc.2016.04.005
29. Smeenk RJ, Hoffmann AL, Hopman WP, van Lin EN, Kaanders JH.
Dose-effect relationships for individual pelvic floor muscles and anorectal
complaints after prostate radiotherapy. Int J Radiat Oncol Biol Phys. (2012)
83:636–44. doi: 10.1016/j.ijrobp.2011.08.007
30. Wortel RC, Incrocci L, Pos FJ, van der Heide UA, Lebesque JV, Aluwini
S, et al. Late side effects after image guided intensity modulated radiation
therapy compared to 3D-conformal radiation therapy for prostate cancer:
results from 2 prospective cohorts. Int J Radiat Oncol Biol Phys. (2016)
95:680–9. doi: 10.1016/j.ijrobp.2016.01.031
31. Wilkins A, Naismith O, Brand D, Fernandez K, Hall E, Dearnaley
D, et al. Derivation of dose/volume constraints for the anorectum
from clinician- and patient-reported outcomes in the chhip trial of
radiation therapy fractionation. Int J Radiat Oncol Biol Phys. (2020)
106:928. doi: 10.1016/j.ijrobp.2020.01.003
32. Rossi L, Bijman R, Schillemans W, Aluwini S, Cavedon C, Witte M,
et al. Texture analysis of 3D dose distributions for predictive modelling
of toxicity rates in radiotherapy. Radiother Oncol. (2018) 129:548–
53. doi: 10.1016/j.radonc.2018.07.027
33. Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM,
et al. Randomized trial of a hypofractionated radiation regimen for the
treatment of localized prostate cancer. J Clin Oncol. (2017) 35:1884–
90. doi: 10.1200/JCO.2016.71.7397
34. Casares-Magaz O, Muren LP, Moiseenko V, Petersen SE, Pettersson
NJ, Høyer M, et al. Spatial rectal dose/volume metrics predict patient-
reported gastro-intestinal symptoms after radiotherapy for prostate
cancer. Acta Oncol. (2017) 56:1507–13. doi: 10.1080/0284186X.2017.13
70130
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Heemsbergen, Incrocci, Pos, Heijmen and Witte. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Oncology | www.frontiersin.org 10 April 2020 | Volume 10 | Article 469
